Vaccine against beta-herpesvirus infection and use thereof
The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.
1. A recombinant human cytomegalovirus (HCMV), wherein said virus comprises a deletion of nucleotides 122631-123667 and 181653-189191 of SEQ ID NO: 20, and wherein SEQ ID NO: 34 is inserted into said virus to replace deleted nucleotides 12263-123667 from SEQ ID NO: 20.
2. The recombinant HCMV according to claim 1 , wherein said virus further comprises a deletion of nucleotides 130671-131242 of SEQ ID NO: 20.
3. The recombinant HCMV according to claim 2 , wherein SEQ ID NO: 35 is inserted into said virus to replace deleted nucleotides 130671-131242 from SEQ ID NO: 20.
4. A recombinant HCMV, wherein said virus comprises a deletion of nucleotides 58443-59622, 181653-189191 of SEQ ID NO: 20, and wherein SEQ ID NO: 32 is inserted into said virus to replace deleted nucleotides 58443-59622 from SEQ ID NO: 20.
5. A recombinant HCMV, wherein said virus comprises a deletion of nucleotides 62130-63260 and 181653-189191 of SEQ ID NO: 20, and wherein SEQ ID NO: 33 is inserted into said virus to replace deleted nucleotides 62130-63260 from SEQ ID NO: 20.
6. The HCMV of claim 5 , further comprising a deletion of nucleotides 58443-59622.
7. The HCMV of claim 6 , wherein SEQ ID NO: 32 is inserted into said virus to replace deleted nucleotides 58443-59622 from SEQ ID NO: 20.
8. An isolated host cell comprising a nucleic acid according to any one of claim 1 , 2 , 3 , 4 , 5 , 6 , or 7 .
9. A pharmaceutical composition comprising the HCMV of any one of claim 1 , 2 , 3 , 4 , 5 , 6 , or 7 , and a pharmaceutically acceptable carrier.